-DOCSTART- -X- O
Human -X- _ B-Patient
adenoviral -X- _ I-Patient
( -X- _ I-Patient
HAd -X- _ I-Patient
) -X- _ I-Patient
vectors -X- _ I-Patient
have -X- _ O
demonstrated -X- _ O
great -X- _ O
potential -X- _ O
as -X- _ O
vaccine -X- _ O
vectors. -X- _ O
Preclinical -X- _ O
and -X- _ O
clinical -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
the -X- _ O
feasibility -X- _ O
of -X- _ O
vector -X- _ O
design -X- _ O
, -X- _ O
robust -X- _ O
antigen -X- _ O
expression -X- _ O
and -X- _ O
protective -X- _ O
immunity -X- _ O
using -X- _ O
this -X- _ O
system. -X- _ O
However -X- _ O
, -X- _ O
clinical -X- _ O
use -X- _ O
of -X- _ O
adenoviral -X- _ O
vectors -X- _ O
for -X- _ O
vaccine -X- _ O
purposes -X- _ O
is -X- _ O
anticipated -X- _ O
to -X- _ O
be -X- _ O
limited -X- _ O
by -X- _ O
vector -X- _ O
immunity -X- _ O
that -X- _ O
is -X- _ O
either -X- _ O
preexisting -X- _ O
or -X- _ O
develops -X- _ O
rapidly -X- _ O
following -X- _ O
the -X- _ O
first -X- _ O
inoculation -X- _ O
with -X- _ O
adenoviral -X- _ O
vectors. -X- _ O
Vector -X- _ O
immunity -X- _ O
inactivates -X- _ O
the -X- _ O
vector -X- _ O
particles -X- _ O
and -X- _ O
rapidly -X- _ O
removes -X- _ O
the -X- _ O
transduced -X- _ O
cells -X- _ O
, -X- _ O
thereby -X- _ O
limiting -X- _ O
the -X- _ O
duration -X- _ O
of -X- _ O
transgene -X- _ O
expression. -X- _ O
Due -X- _ O
to -X- _ O
strong -X- _ O
vector -X- _ O
immunity -X- _ O
, -X- _ O
subsequent -X- _ O
use -X- _ O
of -X- _ O
the -X- _ O
same -X- _ O
vector -X- _ O
is -X- _ O
usually -X- _ O
less -X- _ O
efficient. -X- _ O
In -X- _ O
order -X- _ O
to -X- _ O
circumvent -X- _ O
this -X- _ O
limitation -X- _ O
, -X- _ O
nonhuman -X- _ B-Intervention
adenoviral -X- _ I-Intervention
vectors -X- _ I-Intervention
have -X- _ O
been -X- _ O
proposed -X- _ O
as -X- _ O
alternative -X- _ O
vectors. -X- _ O
In -X- _ O
addition -X- _ O
to -X- _ O
eluding -X- _ O
HAd -X- _ O
immunity -X- _ O
, -X- _ O
these -X- _ O
vectors -X- _ O
possess -X- _ O
most -X- _ O
of -X- _ O
the -X- _ O
attractive -X- _ O
features -X- _ O
of -X- _ O
HAd -X- _ O
vectors. -X- _ O
Several -X- _ O
replication-competent -X- _ O
or -X- _ O
replication-defective -X- _ O
nonhuman -X- _ O
adenoviral -X- _ O
vectors -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
and -X- _ O
investigated -X- _ O
for -X- _ O
their -X- _ O
potential -X- _ O
as -X- _ O
vaccine -X- _ B-Outcome
delivery -X- _ I-Outcome
vectors. -X- _ I-Outcome
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
recent -X- _ O
advances -X- _ O
in -X- _ O
the -X- _ O
design -X- _ O
and -X- _ O
characterization -X- _ O
of -X- _ O
various -X- _ O
nonhuman -X- _ O
adenoviral -X- _ O
vectors -X- _ O
, -X- _ O
and -X- _ O
discuss -X- _ O
their -X- _ O
potential -X- _ O
applications -X- _ O
for -X- _ O
human -X- _ O
and -X- _ O
animal -X- _ O
vaccination -X- _ O
. -X- _ O

